YourVoice.Now Summary
Transparency & AccountabilityCorporate BenefitsA drug mixed just for you would say so on the label — and out-of-state shipments would get reported.
Transparency & Accountability
A pharmacist who mixes drugs to order and ships them out of state would pass on serious side-effect reports. Copies would go to the FDA, to their home state, and to each state that got the drug.
Pharmacists and doctors who send more than 5 percent of their yearly output out of state would file a report. It is due each January 15. It lists their license and how many units went to each state.
Compounded drugs are made for one patient and skip FDA review. The label would have to say that in plain words.
The label would also carry the FDA's MedWatch website and its 1-800 number. The FDA could order more label information later.
Corporate Benefits
A hospital pharmacy that mixes drugs on site for its own patients is left out of the new reports. Other pharmacies are not.
Compounding pharmacies file nothing like this today. The FDA would have to run a shared system to route the reports and hold down the added work.
More about this bill
If you take a drug your pharmacy mixes to order, the label would change. It would have to say the medicine was compounded for one patient and never approved by the FDA. Compounded drugs are mixed or altered to fit one person, so they skip FDA review. The label would also list the FDA's MedWatch website and 1-800 line for reporting a bad reaction. Nothing about your cost or coverage changes. Pharmacists and doctors who ship compounded drugs across state lines would take on new duties. They would pass along any serious side-effect report they get, to the FDA and to each state involved. Those who send more than 5 percent of their output out of state would also file a yearly report. The first would be due January 15 of the first full year after the law takes effect. Hospital pharmacies mixing drugs for their own patients are left out. States could still demand more. The version reported by committee is much narrower than the bill as introduced. Gone are a limit on copying commercial drugs, required inspections of big compounders, and a change to an FDA fee.
Congressional Summary
Congress's official summary of this bill still describes an earlier version of the text, so we have left it out here. You can read it on Congress.gov.
Details
- Congress
- 119th
- Chamber
- Senate
- Status
- summarized
- Action
- Introduced in Senate
- Action Date
- 2026-02-05
- Date Added
- 2026-06-30
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.